Last reviewed · How we verify
NCT03760263: EVOKE-RT
Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus
Phase 4 trial testing Tacrolimus in Transplant;Failure,Kidney in 46 participants. Completed in 1 November 2023.
1 November 2023
Quick facts
| Lead sponsor | Sentara Norfolk General Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 46 |
| Start date | 16 January 2020 |
| Primary completion | 1 November 2023 |
| Estimated completion | 1 November 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Tacrolimus (TACROLIMUS) — full drug profile →
Conditions studied
- Transplant;Failure,Kidney — all drugs for Transplant;Failure,Kidney →
Sponsor
Sentara Norfolk General Hospital
Who can join
Adults 18 to 70, any sex, with Transplant;Failure,Kidney. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03760263
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tacrolimus
Trials testing the same drug.
- NCT07519174 — A Randomized Controlled Trial Comparing the Effectiveness and Safety of Topical Tacrolimus 0.03% Versus Crisaborole 2% i · NA · not yet recruiting
- NCT07249346 — Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease ( · Phase 2 · recruiting
- NCT07349771 — Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoie · Phase 2 · not yet recruiting
- NCT06996119 — Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versu · Phase 1 · not yet recruiting
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
Other recruiting trials for Transplant;Failure,Kidney
Currently open trials in the same condition.
- NCT05613010 — Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant · NA · recruiting
- NCT05449496 — Dietary Intervention to Improve Kidney Transplant Outcomes · NA · active not recruiting
- NCT03737604 — TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant · Phase 4 · recruiting
- NCT03310905 — Abdominal Wall Transplant · NA · recruiting
- NCT03380962 — Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant · Phase 1, PHASE2 · active not recruiting
Other Sentara Norfolk General Hospital trials
Trials by the same sponsor.
- NCT03886077 — Study of Hepatitis Eradication Receiving Protease Inhibitor Administration · recruiting
- NCT04130607 — A Study to Evaluate Strategies for Teaching Effective Use of Diagnostic Tests · NA · completed
- NCT03147430 — Early Detection of Breast Cancer in Women With Suspicious Mammograms · active not recruiting
- NCT03148015 — Novel Molecular Targets for Ductal Carcinoma In Situ (DCIS) · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03760263 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sentara Norfolk General Hospital
- Last refreshed: 29 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03760263.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing